Cargando…

A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers

BACKGROUND: Nonhealing leg ulcers are challenging to manage and cause significant patient morbidity. To promote healing, newer techniques focus on delivering/enhancing dermal matrix components. AIM: The aim of this study was to compare the therapeutic efficacy of autologous platelet-rich plasma (PRP...

Descripción completa

Detalles Bibliográficos
Autores principales: Gehlawat, Tarun, Karia, Umesh K, Shah, Shikha R, Vyas, Harshita Ravindra, Parghi, Mehul B, Doshi, Yashika J, Shah, Bela J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405547/
https://www.ncbi.nlm.nih.gov/pubmed/37554680
http://dx.doi.org/10.4103/JCAS.JCAS_116_22
_version_ 1785085556292583424
author Gehlawat, Tarun
Karia, Umesh K
Shah, Shikha R
Vyas, Harshita Ravindra
Parghi, Mehul B
Doshi, Yashika J
Shah, Bela J
author_facet Gehlawat, Tarun
Karia, Umesh K
Shah, Shikha R
Vyas, Harshita Ravindra
Parghi, Mehul B
Doshi, Yashika J
Shah, Bela J
author_sort Gehlawat, Tarun
collection PubMed
description BACKGROUND: Nonhealing leg ulcers are challenging to manage and cause significant patient morbidity. To promote healing, newer techniques focus on delivering/enhancing dermal matrix components. AIM: The aim of this study was to compare the therapeutic efficacy of autologous platelet-rich plasma (PRP), autologous platelet-rich fibrin matrix (PRFM), recombinant human epidermal growth factor (rhEGF), and collagen particles in treating nonhealing leg ulcers. MATERIALS AND METHODS: Open, randomized prospective study was conducted in a single tertiary center over 2 years where after fulfilling the criteria, randomization was done into four groups. Group A: Autologous PRP (double spin, manual method, weekly); Group B: Autologous PRFM (weekly); Group C: rhEGF (daily application); and Group D: Collagen particles (weekly) along with cleansing, debris removal, and wound dressing. Treatment endpoints were complete healing/6 months of treatment, whichever was earlier. Follow-up was done two weekly by clinical assessment, photographs, and measurement of the ulcer area. Epi info 7 software was used for statistical analysis. RESULTS: A total of 48 patients completed the study, 12 in each group, with mean age: 42.37 ± 4.56 years and male-to-female ratio 2.6:1. Underlying etiology was varicosities (43.75%), traumatic (25%), diabetes (22.91%), and leprosy (8.34%). At baseline, all groups were comparable in terms of patient and ulcer characteristics. Complete healing was seen in 79.17% at the end of 12 weeks: 91.67% of patients from Groups A and B each, and 66.67% from Groups C and D each. The mean time to complete healing was 6.9 ± 2.5 weeks, the least in Group B (4.73 ± 2.3 weeks). Differences between excellent (≥75%) ulcer healing across all groups were statistically significant at the end of 8 weeks where Group B showed maximum improvement. No major adverse events were seen. CONCLUSION: PRFM resulted in relatively faster ulcer healing compared with other modalities.
format Online
Article
Text
id pubmed-10405547
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-104055472023-08-08 A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers Gehlawat, Tarun Karia, Umesh K Shah, Shikha R Vyas, Harshita Ravindra Parghi, Mehul B Doshi, Yashika J Shah, Bela J J Cutan Aesthet Surg Original Article BACKGROUND: Nonhealing leg ulcers are challenging to manage and cause significant patient morbidity. To promote healing, newer techniques focus on delivering/enhancing dermal matrix components. AIM: The aim of this study was to compare the therapeutic efficacy of autologous platelet-rich plasma (PRP), autologous platelet-rich fibrin matrix (PRFM), recombinant human epidermal growth factor (rhEGF), and collagen particles in treating nonhealing leg ulcers. MATERIALS AND METHODS: Open, randomized prospective study was conducted in a single tertiary center over 2 years where after fulfilling the criteria, randomization was done into four groups. Group A: Autologous PRP (double spin, manual method, weekly); Group B: Autologous PRFM (weekly); Group C: rhEGF (daily application); and Group D: Collagen particles (weekly) along with cleansing, debris removal, and wound dressing. Treatment endpoints were complete healing/6 months of treatment, whichever was earlier. Follow-up was done two weekly by clinical assessment, photographs, and measurement of the ulcer area. Epi info 7 software was used for statistical analysis. RESULTS: A total of 48 patients completed the study, 12 in each group, with mean age: 42.37 ± 4.56 years and male-to-female ratio 2.6:1. Underlying etiology was varicosities (43.75%), traumatic (25%), diabetes (22.91%), and leprosy (8.34%). At baseline, all groups were comparable in terms of patient and ulcer characteristics. Complete healing was seen in 79.17% at the end of 12 weeks: 91.67% of patients from Groups A and B each, and 66.67% from Groups C and D each. The mean time to complete healing was 6.9 ± 2.5 weeks, the least in Group B (4.73 ± 2.3 weeks). Differences between excellent (≥75%) ulcer healing across all groups were statistically significant at the end of 8 weeks where Group B showed maximum improvement. No major adverse events were seen. CONCLUSION: PRFM resulted in relatively faster ulcer healing compared with other modalities. Wolters Kluwer - Medknow 2023 /pmc/articles/PMC10405547/ /pubmed/37554680 http://dx.doi.org/10.4103/JCAS.JCAS_116_22 Text en Copyright: © 2023 Journal of Cutaneous and Aesthetic Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Gehlawat, Tarun
Karia, Umesh K
Shah, Shikha R
Vyas, Harshita Ravindra
Parghi, Mehul B
Doshi, Yashika J
Shah, Bela J
A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers
title A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers
title_full A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers
title_fullStr A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers
title_full_unstemmed A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers
title_short A Comparative Study on Therapeutic Efficacy of Autologous Platelet-rich Plasma, Autologous Platelet-rich Fibrin Matrix, Recombinant Human Epidermal Growth Factor, and Collagen Particles in Nonhealing Leg Ulcers
title_sort comparative study on therapeutic efficacy of autologous platelet-rich plasma, autologous platelet-rich fibrin matrix, recombinant human epidermal growth factor, and collagen particles in nonhealing leg ulcers
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405547/
https://www.ncbi.nlm.nih.gov/pubmed/37554680
http://dx.doi.org/10.4103/JCAS.JCAS_116_22
work_keys_str_mv AT gehlawattarun acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT kariaumeshk acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT shahshikhar acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT vyasharshitaravindra acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT parghimehulb acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT doshiyashikaj acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT shahbelaj acomparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT gehlawattarun comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT kariaumeshk comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT shahshikhar comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT vyasharshitaravindra comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT parghimehulb comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT doshiyashikaj comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers
AT shahbelaj comparativestudyontherapeuticefficacyofautologousplateletrichplasmaautologousplateletrichfibrinmatrixrecombinanthumanepidermalgrowthfactorandcollagenparticlesinnonhealinglegulcers